We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Kos, Barr Settle Niaspan Patent Litigation With Unusual Deal

Law360 (April 13, 2005, 12:00 AM EDT) -- Barr Pharmaceuticals Inc. and Kos Pharmaceuticals Inc. have penned an unusual settlement agreement to put an end to their patent litigation over Kos' cholesterol lowering drugs Niaspan and Advicor, the two companies said Wednesday.

Under the seven-year deal, Barr subsidiary Duramed Pharmaceuticals will co-promote Niaspan and Advicor -- as well as any future dosages or modified versions -- to obstetricians, gynecologists and other women's healthcare practitioners in exchange for royalties on quarterly and yearly sales.

Kos will help train a Duramed sales force of 40 to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.